Paycom Software Inc (PAYC) Stock Price Today
Aura AI Summary
Key Stats
- $10.19BMarket Cap
- 658,927Volume
- TechnologySector
- $240.5252W High
- $113.5952W Low
- 84 DaysTypical Hold Time
- $10.97BEnterprise Value
- 0.66%Div Yield
- -Trading Activity
Track Paycom Software Inc (PAYC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Paycom Software Inc has traded between a low of $113.59 and a high of $240.52, highlighting its annual price range. Buy and sell Paycom Software Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Most Recent News
La-Z-Boy director Janet Kerr sells 3,653 shares for $116,000.
Janet Kerr, a director at La-Z-Boy, has sold 3,653 shares of the company, generating $116,000 from the transaction. This sale could indicate a personal financial decision or portfolio adjustment, but it may also attract investor attention regarding i...

AI and crypto stocks surge as TJGC plans AI expansion and FWDI updates SkyAI acquisition offer
Shares of TJGC Group Limited jumped nearly 54% after announcing plans to expand into AI hardware, led by new leadership in electronics manufacturing. Forward Industries rose 24% following an updated acquisition proposal for SkyAI, offering a 50% prem...

Replimune sued for allegedly misleading investors on cancer drug trial data, shares plunge after FDA rejection.
Replimune Group faces a class action lawsuit alleging it misled investors about the efficacy and viability of its lead cancer drug candidate RP1. The FDA rejected Replimune's Biologics License Application (BLA) for RP1 combined with nivolumab due to ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.